We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Theseus Pharmaceuticals Inc | NASDAQ:THRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.06 | 4.05 | 3.91 | 0 | 01:00:00 |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 12 | | | |
| | | | 29 | | | |
| | | | 29 | | | |
| | | | 29 | | | |
| | | | 30 | | | |
| | | | 37 | | | |
| | | | I-1 | | | |
| | | | II-1 | | |
Name of Executive Officer or Director
(including former executive officers) |
| |
Number of
Shares (#) |
| |
Cash Consideration
for Shares ($) |
| ||||||
Timothy P. Clackson, Ph.D.
|
| | | | 376,693 | | | | | | 1,525,607 | | |
Bradford D. Dahms
|
| | | | 8,150 | | | | | | 33,008 | | |
William C. Shakespeare, Ph.D.
|
| | | | 649,329 | | | | | | 2,629,782 | | |
Victor M. Rivera, Ph.D.
|
| | | | 651,399 | | | | | | 2,638,166 | | |
David P. Kerstein, M.D.
|
| | | | 7,656 | | | | | | 31,007 | | |
Iain Dukes, D.Phil.
|
| | | | 388,324 | | | | | | 1,572,712 | | |
Carl Gordon, Ph.D.
|
| | | | — | | | | | | — | | |
Don Hayden, M.B.A.
|
| | | | 10,100 | | | | | | 40,905 | | |
Michael Rome, Ph.D.
|
| | | | — | | | | | | — | | |
Steven Stein, M.D.
|
| | | | — | | | | | | — | | |
Kathy Yi, M.B.A.
|
| | | | — | | | | | | — | | |
Name of Executive Officer or Director
(including former executive officers) |
| |
Number of Shares
Subject to In-the- Money Options (#) |
| |
Cash Consideration
for Stock Options ($) |
| ||||||
Timothy P. Clackson, Ph.D.
|
| | | | 1,148,583 | | | | | | 22,972 | | |
Bradford D. Dahms
|
| | | | 332,114 | | | | | | 6,642 | | |
William C. Shakespeare, Ph.D.
|
| | | | 352,192 | | | | | | 353,038 | | |
Victor M. Rivera, Ph.D.
|
| | | | 190,875 | | | | | | 349,812 | | |
David P. Kerstein, M.D.
|
| | | | 332,114 | | | | | | 1,093,925 | | |
Iain Dukes, D.Phil.
|
| | | | 441,959 | | | | | | 1,286,355 | | |
Carl Gordon, Ph.D.
|
| | | | — | | | | | | — | | |
Don Hayden, M.B.A.
|
| | | | — | | | | | | — | | |
Michael Rome, Ph.D.
|
| | | | — | | | | | | — | | |
Steven Stein, M.D.
|
| | | | — | | | | | | — | | |
Kathy Yi, M.B.A.
|
| | | | 99,634 | | | | | | 1,993 | | |
Name of Executive Officer or Director
(including former executive officers) |
| |
Number of
Theseus RSUs (#) |
| |
Cash Consideration
for Theseus RSUs ($) |
| ||||||
Timothy P. Clackson, Ph.D.
|
| | | | 19,962 | | | | | | 80,846 | | |
Bradford D. Dahms
|
| | | | 17,500 | | | | | | 70,875 | | |
William C. Shakespeare, Ph.D.
|
| | | | 2,656 | | | | | | 10,757 | | |
Victor M. Rivera, Ph.D.
|
| | | | 9,141 | | | | | | 37,021 | | |
David P. Kerstein, M.D.
|
| | | | 9,844 | | | | | | 39,868 | | |
Iain Dukes, D.Phil.
|
| | | | 3,250 | | | | | | 13,163 | | |
Carl Gordon, Ph.D.
|
| | | | 3,250 | | | | | | 13,163 | | |
Don Hayden, M.B.A.
|
| | | | 3,250 | | | | | | 13,163 | | |
Michael Rome, Ph.D.
|
| | | | — | | | | | | — | | |
Steven Stein, M.D.
|
| | | | 3,250 | | | | | | 13,163 | | |
Kathy Yi, M.B.A.
|
| | | | 3,250 | | | | | | 13,163 | | |
| | |
Estimated Company Obligations Prior to Liquidation
|
| | |
Estimated Company Obligations
During Holdback Period |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
December
|
| |
January
|
| |
February
|
| |
March
|
| |
April
|
| |
May
|
| |
June
|
| | |
Year 1
|
| |
Year 2
|
| |
Year 3
|
| ||||||||||||||||||||||||||||||
Beginning Cash
|
| | | $ | 217,522,922 | | | | | $ | 207,816,622 | | | | | $ | 206,948,474 | | | | | $ | 205,606,352 | | | | | $ | 204,193,984 | | | | | $ | 203,294,787 | | | | | $ | 202,545,376 | | | | | | $ | 59,130,900 | | | | | $ | 56,396,727 | | | | | $ | 53,858,727 | | |
Operating Expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
External R&D
|
| | | | 707,803 | | | | | | 714,179 | | | | | | 416,662 | | | | | | 387,668 | | | | | | 195,950 | | | | | | 134,276 | | | | | | 23,439 | | | | | | | 202,173 | | | | | | — | | | | | | — | | |
External G&A
|
| | | | 3,545,145 | | | | | | 1,007,095 | | | | | | 697,957 | | | | | | 711,437 | | | | | | 673,964 | | | | | | 673,964 | | | | | | 693,964 | | | | | | | 1,500,000 | | | | | | 1,500,000 | | | | | | 1,500,000 | | |
Personnel expenses(1)
|
| | | | 2,917,146 | | | | | | 1,107,625 | | | | | | 1,255,384 | | | | | | 1,051,144 | | | | | | 545,164 | | | | | | 445,052 | | | | | | 386,640 | | | | | | | 1,200,000 | | | | | | 1,200,000 | | | | | | 1,200,000 | | |
Lease Termination Fees(2)
|
| | | | 4,665,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Total operating expenses
|
| | | | 11,835,094 | | | | | | 2,828,899 | | | | | | 2,370,003 | | | | | | 2,150,248 | | | | | | 1,415,078 | | | | | | 1,253,292 | | | | | | 1,104,043 | | | | | | | 2,902,173 | | | | | | 2,700,000 | | | | | | 2,700,000 | | |
Interest and Accretion
|
| | | | 920,000 | | | | | | 1,125,000 | | | | | | 800,000 | | | | | | 550,000 | | | | | | 400,000 | | | | | | 400,000 | | | | | | 400,000 | | | | | | | 168,000 | | | | | | 162,000 | | | | | | 153,000 | | |
Net loss
|
| | | | (10,915,094) | | | | | | (1,703,899) | | | | | | (1,570,003) | | | | | | (1,600,248) | | | | | | (1,015,078) | | | | | | (853,292) | | | | | | (704,043) | | | | | | | (2,734,173) | | | | | | (2,538,000) | | | | | | (2,547,000) | | |
Cash adjustments: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Other WC adjustments
|
| | | | 1,124,913 | | | | | | 751,870 | | | | | | 144,000 | | | | | | 104,000 | | | | | | 32,000 | | | | | | 20,000 | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | |
Non-cash Insurance Amortization
|
| | | | 83,881 | | | | | | 83,881 | | | | | | 83,881 | | | | | | 83,881 | | | | | | 83,881 | | | | | | 83,881 | | | | | | 83,881 | | | | | | | — | | | | | | — | | | | | | — | | |
Sub-total adjustments to cash
|
| | | | 1,208,794 | | | | | | 835,751 | | | | | | 227,881 | | | | | | 187,881 | | | | | | 115,881 | | | | | | 103,881 | | | | | | 83,881 | | | | | | | — | | | | | | — | | | | | | — | | |
Monthly cash burn
|
| | | | (9,706,300) | | | | | | (868,148) | | | | | | (1,342,122) | | | | | | (1,412,368) | | | | | | (899,197) | | | | | | (749,411) | | | | | | (620,162) | | | | | | | (2,734,173) | | | | | | (2,538,000) | | | | | | (2,547,000) | | |
Ending Cash
|
| | | $ | 207,816,622 | | | | | $ | 206,948,474 | | | | | $ | 205,606,352 | | | | | $ | 204,193,984 | | | | | $ | 203,294,787 | | | | | $ | 202,545,376 | | | | | $ | 201,925,214 | | | | | | $ | 56,396,727 | | | | | $ | 53,858,727 | | | | | $ | 51,311,727 | | |
Other payables due at liquidation(3)
|
| | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | |
|
(4,822,214)
|
| | | | | | | | | | | | | | | | | | | | |
Net Cash
|
| | | | 207,816,622 | | | | | | 206,948,474 | | | | | | 205,606,352 | | | | | | 204,193,984 | | | | | | 203,294,787 | | | | | | 202,545,376 | | | | | | 197,103,000 | | | | | | | | | | | | | | | | | | | | | |
Distribution of 70% (Holdback 30%)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 137,972,100 | | | | | | | | | | | | | | | | | | | | | |
Remaining cash after distribution
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 59,130,900 | | | | | | | | | | | | | | | | | | | | | |
|
Distribution of 70%
|
| | | $ | 137,972,100 | | |
|
Total Shares Outstanding
|
| | |
|
45,584,772
|
| |
|
Price per Share for distribution
|
| | | $ | 3.03 | | |
|
Present value of 75% of holdback to be paid out after 3 years using a 5% discount rate(4)
|
| | | $ | 33,243,749 | | |
|
Total Shares Outstanding
|
| | | | 45,584,772 | | |
|
Price per Share
|
| | | $ | 0.73 | | |
|
Total amount paid out per Share
|
| | | $ | 3.76 | | |
1 Year Theseus Pharmaceuticals Chart |
1 Month Theseus Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions